Jing Tian Raises NT$192 Million via Cash Increase to Accelerate Clinical Development and Commercialization of Lead Drug

Jing Tian (6917-TW) has received regulatory approval for its cash capital increase to issue new shares this year. The company plans to issue 6,000 new shares at NT$32 per share, raising NT$192 million. Jing Tian stated that the proceeds will primarily be allocated to mid-to-late stage clinical trials of its lead drug APC201 and to supplement working capital.

APC201, developed by Jing Tian, is a topical foam formulation drug targeting localized knee osteoarthritis pain, developed under the 505(b)(2) pathway. The drug has completed Phase 1/2a clinical trials in Australia, confirming its safety and preliminary efficacy. The company is now planning global multicenter Phase 2b/3 clinical trials and seeking international licensing partnerships.

Jing Tian emphasized that the funds raised from this capital increase will be directly invested in the Phase 2b trial of APC201, accelerating product development and enabling early commercialization to capture a share of the global topical arthritis pain relief market, which exceeds USD 1.5 billion.

The company’s other lead drug, APC101, indicated for systemic post-herpetic neuralgia, has received regulatory approval to enter Phase 2b/3 clinical trials in both Australia and the United States, with progress in line with expectations.

Jing Tian’s revenue for the first seven months of the year reached NT$6.77 million, a year-on-year increase of over 77 times, setting a new record for the same period. Chairman Amy Wang stated that the revenue growth was driven by effective distribution strategy adjustments with partner E-Shin Pharmaceutical, licensing income from co-development, and strong sales growth of the two key products: Pi Ma Le Cream and Ai Mi Hair Growth Lotion.